Use of pegylated recombinant filgrastim (Pegfilgrastim) in patients with acute myeloid leukemia: Pharmacokinetics and impact on leukocyte recovery

Leukemia

Volumn 22, Issue 6, 2008, Pages 1284-1285

  Fiegl, M ^a   Hiddemann, W ^a   Braess, J ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; MITOXANTRONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HUMAN; LEUKOCYTE COUNT; MALE; NEUTROPENIA; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

EID: 45149126628     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2405038     Document Type: Article

References (6)

1. Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdallah R et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. N Engl J Med 1995; 332: 1678-1683.
2. Heil G, Hoelzer D, Sanz MA, Lechner K, Noens L, Szer J et al. Long-term survival data from a phase 3 study of Filgrastim as an adjunct to chemotherapy in adults with de novo acute myeloid leukemia. Leukemia 2006; 20: 404-409.
3. Ohno R, Tomonaga M, Kobayashi T, Kanamaru A, Shirakawa S, Masaoka T et al. Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 1990; 323: 871-877.
4. Kern W, Aul C, Maschmeyer G, Kuse R, Kerkhoff A, Grote-Metke A et al Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukaemia. German AML Cooperative Group. Ann Hematol 1998; 77: 115-122.
5. Johnston E, Crawford J, Blackwell S, Bjurstrom T, Lockbaum P, Roskos L et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000; 18: 2522-2528.
6. Yang BB, Kido A, Shibata A. Serum pegfilgrastim concentrations during recovery of absolute neutrophil count in patients with cancer receiving pegfilgrastim after chemotherapy. Pharmacotherapy 2007; 27: 1387-1393.